EXHIBIT 10.7
Certain identified information has been excluded from the exhibit because it is
both (i) not material and (ii) would likely cause competitive harm to the
Company, if publicly disclosed. Double asterisks denote omissions.

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT1. CONTRACT ID CODEPAGE OF
PAGES12
2. AMENDMENT/MODIFICATION NO.
P000024
3. EFFECTIVE DATE
See Block 16C
4. REQUISITION/PURCHASE REQ. NO.
5. PROJECT NO. (If applicable)
6. ISSUED BY    CODEASPR/BARDA
7. ADMINISTERED BY (If other than Item 6) CODE
ASPR/BARDAO2ASPR/BARDA
200 Independence Ave., S.W.
Room 640 - G
Washington, D.C. 20201ASPR-BARDA
330 Independence Ave, SW, Rm G640
Washington DC 20201
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)
(x)9A. AMENDMENT OF SOLICITATION NO.

EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC
EMERGENT MANUFACTURING OPERATIONS B
5901 E LOMBARD ST
BALTIMORE MD 212246824
9B. DATED (SEE ITEM 11)
x10A. MODIFICATION OF CONTRACT/ORDER NO.HHSO100201200004I
10B. DATED (SEE ITEM 13)
CODE 1410445FACILITY CODE06/15/201211. THIS ITEM ONLY APPLIES TO AMENDMENTS OF
SOLICITATIONS
 The above numbered solicitation is amended as set forth in Item 14. The hour
and date specified for receipt of Offers     is extended, is not extended.
Offers must acknowledge receipt of this amendment prior to the hour and date
specified in the solicitation or as amended, by one of the following methods:
(a) By completing Items 8 and 15, and returning _________ copies of the
amendment; (b) By acknowledging receipt of this amendment on each copy of the
offer submitted; or
(c) By separate letter or electronic communication which includes a reference to
the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE
RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND
DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this
amendment you desire to change an offer already submitted, such change may be
made by letter or electronic communication, provided each letter or electronic
communication makes reference to the solicitation and this amendment, and is
received prior to the opening hour and date specified.
12. ACCOUNTING AND APPROPRIATION DATA (If required)
See Schedule
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. IT MODIFIES THE
CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.CHECK ONE
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET
FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE
CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH
IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

x
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
FAR 43.103 (a) (3) – Mutual Agreement of Both Parties
D. OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor is not, is required to sign this document and return
____1____ copies to the issuing office.
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings,
including solicitation/contract subject matter where feasible.)
Tax ID Number: [**]
DUNS Number: [**]
The purpose of this cost modification is to:
A. Incorporate the attached proposal which describes the enhancing of the ADM
facility Core Service Capabilities for Bioreactor Infrastructure to the
Biomedical Advanced Research and Development Authority (BARDA) under our current
Prime Contract No. HHS0100201200004I.
B. This project includes the purchase, installation and qualification of [**].
This acquisition of additional equipment allows for the expansion of the
facility with flexibility to be able to increase large scale production.
C. Prime Contract No. HHS0100201200004I is hereby modified as follows in
accordance with the
Continued . . .
Except as provided herein, all terms and conditions of the document referenced
in Item 9A or 10A, as heretofore changed, remains unchanged and in full force
and effect.
15A. NAME AND TITLE OF SIGNER (Type or print).
Patrick D. Saam, VP Government Contracting & Accounting
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
Monica Watson
15B. CONTRACTOR/OFFEROR

/s/ Patrick D. Saam    
(Signature of person authorized to sign)
15C. DATE SIGNED

8/28/2020
Digitally signed by [**] - S
16B. UNITED STATES OF AMERICA
/s/ Monica Watson
    
(Signature of Contracting Officer)
16C. DATE SIGNED

8/28/2020

Previous edition unusable    STANDARD FORM 30 (Rev. 11/2016)
    Prescribed by GSA     FAR (48 CFR) 53.243

--------------------------------------------------------------------------------

CONTINUATION SHEET
REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201200004I/P00024
PAGE OF22
NAME OF OFFEROR OR CONTRACTOR
EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC 1410445
ITEM No.
(A)
SUPPLIES/SERVICES
(B)
QUANTITY
(C)
UNIT
(D)
UNIT PRICE
(E)
AMOUNT
(F)
Attached proposal.

NSN 7540-01-152-8067    OPTIONAL FORM 336 (4-86)
Sponsored by GSA
FAR (48 CFR) 53.110
image_01.jpg [image_01.jpg]

“Change Order Proposal for Enhancing/Expanding Core Capabilities of the
ADM-Bioreactors”
Proposal Submitted for Consideration to:
Biomedical Advanced Research and Development Authority (BARDA) under Contract
HHSO100201200004I
Change Order Proposal    June 25, 2020

Offeror:
Emergent Manufacturing Operations Baltimore LLC (EMOB)
5901 East Lombard St. Baltimore, MD 21224 DUNS: [**]
CAGE CODE: 6EBP9
Type: Large Business

Proposed Period of Performance:
06/15/2012 – 06/14/2024

Emergent’s Program Contact:
Syed Husain
SVP, BU, Head-CDMO
400 Professional Drive Gaithersburg, MD 20879 Office: [**]
Fax: [**]
Cell: [**]
Email: [**]

Emergent’s Contracts Contact:
[**]
400 Professional Drive, Suite 400 Gaithersburg, MD 20879
Phone: [**]
Email: [**]

Prepared for (via email):
[**]
Email: [**]

--------------------------------------------------------------------------------

This proposal includes data that shall not be disclosed outside the Government
and shall not be duplicated, used, or disclosed—in whole or in part—for any
purpose other than to evaluate this proposal. If, however, a contract is awarded
to this offeror as a result of— or in connection with—the submission of this
data, the Government shall have the right to duplicate, use, or disclose the
data to the extent provided in the resulting contract. This restriction does not
limit the Government’s right to use information contained in this data if it is
obtained from another source without restriction. The data subject to this
restriction are contained on all marked pages.

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

Change Order Proposal

1.0 Introduction

Emergent Manufacturing Operations Baltimore LLC (Bayview) is pleased to submit
this proposal for further enhancing the ADM facility’s Core Service Capabilities
for Bioreactor Infrastructure to the Biomedical Advanced Research and
Development Authority (BARDA) under our current Prime Contract No. HHS01
00201200004I.

This project includes the [**]. This acquisition of additional equipment allows
for the expansion of the facility with flexibility to be able to increase large
scale production throughput with parallel suite capability as follows:

•Area [**] and [**]: up to [**] per area, currently up to [**] per area
•Area [**]: up to [**], currently up to [**]

[**].

This Proposal outlines and describes the resources underpinning our approach and
the costs of applying those resources.

1.1 Contract Type and Period of Performance
1.1.1. Line Item Contract Type
Emergent submits this Proposal for incorporation under Contract
HHS0100201200004I, awarded June 15, 2012 by BARDA to Emergent.

1.1.1.1. Cost
The Cost SLIN proposed includes only Emergent’s Total Cost (with no profit or
fee) and is as follows:

subCLIN 0002.7- “Core Service Capabilities–Bioreactor Infrastructure”

1.1.1.2 Cost Share
The Cost-share SLIN proposed with this offer, and the respective share
percentage, is as follows:

1
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

Change Order Proposal

subCLIN 0002.7- “Core Service Capabilities–Bioreactor Infrastructure”    [**]
(USG/Emergent)

1.1.2 Proposal Period of Performance
For the purposes of this proposal, the pricing assumes the Contract itself shall
extend the end date for the period of performance for the Base Period from
06/14/2020 to 06/14/2024.

1.2 Period of Validity
This Proposal shall remain valid for a period of 60 days from the date on the
cover page of this submission.

1.3 Commitment
Emergent acknowledges that there may be additional changes required under the
current contract to properly incorporate the work proposed and hereby commits
that Emergent shall work together in good faith with BARDA’s ADM Team to
finalize an approach (and subsequent contract modification) acceptable to both
parties.

2.0 PRICE TABLES
Set out below is Emergent’s proposed price tables detailing the CLIN offered for
the new Enhanced Core Service Capabilities for Bioreactors under an additional
proposed subCLIN 0002.7 – “Core Service Capabilities – Bioreactor
Infrastructure”:

subCLINItem DescriptionCost Share USG/KtrContractor Cost ShareUSG Cost ShareNot
to Exceed Total Cost0002.7Core Service Capabilities - BioReactor
Infrastructure[**][**][**][**]

2.1 CLIN Funding Realignment
Emergent is proposing the addition of this new subCLIN to the contract as a
zero-dollar change order proposal assuming that the current funds allocated to
existing CLIN 0002 on the contract can be re-allocated to cover the proposed
subCLIN 0002.7 amount outlined in the above table. As such, no additional
funding is required on the Contract under this proposed change request. The USG
current cost share obligation of $[**] shall remain unchanged.

2
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

Change Order Proposal

Emergent proposes that excess funds that are presently assigned to subCLIN
0002.3 - “Licensure of Pandemic Flu Vaccine at [**] Facility” be allocated to
this new CLIN.

Coupled with our prior request for realignment of funds under the ADM CLINs, we
request the funding be changed as follows:

Was:

subCLINItem DescriptionCost Share USG/KtrContractor Cost ShareUSG Cost ShareNot
to Exceed Total Cost0002.1[**] Pilot Plant-Design Construction,
CQV[**][**][**][**]0002.2[**]-Design, Construction,
CQV[**][**][**][**]0002.3Licensure of Pandemic Flu Vaccine at [**]
Facility[**][**][**][**]0002.4Project
Management[**][**][**][**]0002.5Security[**][**][**][**]0002.6
Workforce Development Program (Plan Development)
[**][**][**][**]

Totals $[**] $[**]        $[**]
Now Read: (all proposed changes in bold font)

subCLINItem DescriptionCost Share USG/KtrContractor Cost ShareUSG Cost ShareNot
to Exceed Total Cost0002.1[**] Pilot Plant-Design Construction,
CQV[**][**][**][**]0002.2[**]-Design, Construction,
CQV[**][**][**][**]0002.3Licensure of Pandemic Flu Vaccine at [**]
Facility[**][**][**][**]0002.4Project
Management[**][**][**][**]0002.5Security[**][**][**][**]0002.6
Workforce Development Program (Plan Development)
[**][**][**][**]0002.7Core Service Capabilities – BioReactor
Infrastructure[**][**][**][**]

“The subcontractor identified in the attached proposal are approved by the
government for purposes of performance of subCLIN 0002.27”

3
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

Change Order Proposal

3.0 Assumptions
3.1 Proposed Assumptions
Pricing for the overall program is based on the following assumptions:
–Emergent’s schedule and pricing are based on the activities proposed. Any
changes to the scope, quantity and type of equipment and/or services to be
provided may necessitate a change to the proposed prices and schedule.

–This offer assumes that the period of performance for the Base CLINs 0001, 0002
and 0003 shall be extended as cited in Section 1.1.2, or as amended.

–As both parties have successfully done in the past on this contract, Emergent
assumes that as we progress further on the scope of work under CLIN 0002, that
the re-alignment of the cost share funding listed for each subCLIN under CLIN
0002s may be required to be adjusted in future.

4.0 Cost Narrative
4.1 Direct Labor
4.1.1. Uncompensated Overtime
Uncompensated overtime has not been proposed for this effort.
4.1.2. Productive Man-Year
The productive man-year proposed for this effort is 2,080. The calculation is
based on the available hours in a calendar year (52 weeks x 40 hours per week).
4.1.3. Level of Effort (LOE)
The LOE proposed for each position was estimated based on the work requirements
and Emergent’s experience with similar tasks.
4.1.4. Direct Labor Escalation
Direct labor rates have been escalated by [**]% commencing January 1st of each
contract year which is consistent with industry standard. Emergent issues annual
merit/cost of living adjustments to its employees and takes account of any
anticipated promotions for proposed personnel on January 1st. Emergent does not
always award a [**]% annual merit/cost of living adjustments.

4
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

Change Order Proposal

4.2 Other Direct Costs
4.2.1 Subcontractors
Proposed subcontractors and subcontractor costs for the following are based on
estimated pricing used as a basis of estimate for tasks similar in scope.
Breakdowns of Subcontractor costs with task description are included in Table 1,
below.

Table 1 – “Emergent’s Proposed Subcontractors” below, lists our proposed
subcontractors and provides the following information: Subcontractor name, SLIN,
basis of selection, and total cost and summary of the source used:

subCLINSubcontractorBasis of SelectionTotal
CostsSource0002.7[**][**][**][**]0002.7[**][**][**][**]0002.7[**][**][**][**]0002.7[**][**][**][**]0002.7[**][**][**][**]0002.7[**][**][**][**]0002.7[**][**][**][**]

Subcontractor costs are based on estimates from similar work performed by
existing or anticipated vendors.
4.2.2. Travel
Emergent is not proposing any costs for travel in this offer.

4.2.3. Materials/Supplies
Emergent is not proposing any costs for materials or supplies in this offer.

4.2.4. Equipment
Emergent shall require the acquisition of certain equipment in the fulfillment
of the work proposed. We have included Table 2 below detailing the equipment and
the direct cost proposed. Quotes for this equipment is on file at Emergent.

Equipment cost share assumes that Emergent will own and have title to the
equipment purchased as part of this proposed effort.

5
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

Change Order Proposal

EQUIPMENT COSTS

Task DescriptionITEMDirect $ssubCLIN 0002.7[**][**]subCLIN 0002.7[**][**]subCLIN
0002.7[**][**]subCLIN 0002.7[**][**]subCLIN 0002.7[**][**]subCLIN
0002.7[**][**]subCLIN 0002.7[**][**]Grand Total$    [**]

Table 2: Equipment Proposed

4.3 Indirect Costs
The methodology used to calculate Emergent’s proposed Total Cost/Cost Share
pricing utilized indirect costs detailed in the sections below and are based on
rates from the 2019 Forward Pricing Rates for Emergent BioSolutions – Federal
Segment submitted to the National Institute of Health (NIH) Division of
Financial Services (DFAS) on July 22, 2019. This Forward Pricing Indirect rate
proposal provides forward pricing to be used from the date of submittal onward
and provides rates for our indirect cost elements (Fringe, OH, Material &
Subcontractor Handling and G&A). A pdf copy is embedded in this submission for
your reference, as follows:

[**]
4.3.1 Fringe
Emergent’s fringe rate is [**]%. The fringe rate is applied to all direct labor
costs. This fringe rate as calculated by dividing the projected cost of fringe
benefits by the projected salary base.
4.3.2 Development Overhead
Emergent has utilized its overhead rate titled “R&D Overhead (Bayview)” for this
effort in concert with our disclosed practices, which is [**]% and has been
applied to all direct labor and fringe benefit costs. This rate was calculated
by dividing the projected cost of overhead expenses by the projected salary base
plus applicable fringe benefits.
4.3.3 General and Administrative
Emergent’s General and Administrative (G&A) rate is [**]% and has been applied
to all direct costs and equipment costs proposed herein (excluding Subcontractor
and material costs, which are not part of the basis of allocation). This rate
was calculated by dividing projected

6
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

Change Order Proposal

G&A costs by a base composed of direct project cost (excluding subcontracts and
materials) and Federal Acquisition Regulation (FAR) unallowable costs.
4.3.4 Material and Subcontractor Handling
Emergent’s Material and Subcontractor Handling (M&SH) rate is [**]% and has been
applied to subcontractor and material costs proposed herein. This rate includes
the costs associated with personnel responsible for aspects of purchasing
materials, issuing solicitations, processing subcontractor’s agreements and
purchase orders. The base used to calculate this rate consists of materials and
subcontractor cost (except for subcontractor cost related to capital assets).
4.3.5 Indirect Cost Rates, Forward Pricing/Outyears
Emergent has straight-lined the indirect ceiling rates and as such, there is no
variance in the indirect cost rates proposed for each contract year.

7
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

5.0 COST SUMMARIES

1.Cost Summary
The following tables shows the total for the subCLIN 0002.7, by Element of Cost
proposed, and broken down per the proposed Cost Share percentages;
SUMMARY - By Element of Cost

DescriptionRateGrand totalGovernment Portion
([**]%)Emergent ([**]%)TOTAL [**] DEVELOPMENT LABOR HOURS[**]TOTAL
HOURS[**][**][**]TOTAL [**] DEVELOPMENT LABOR COST[**][**][**]TOTAL DIRECT LABOR
COST[**][**][**]FRINGE BENEFITS [**] DEVELOPMENT LABOR[**][**][**][**]TOTAL
FRINGE BENEFITS[**][**][**]TOT DIRECT LABOR & FRINGE BENEFITS BALTIMORE
DEVELOPMENT[**][**][**]TOTAL DIRECT AND FRINGE[**][**][**][**] DEVELOPMENT
OVERHEAD[**][**][**][**]TOTAL OVERHEAD[**][**][**]MATERIALS AND
SUPPLIESPROFESSIONAL TRAVELEQUIPMENT[**][**][**]CONSULTANTSOTHER DIRECT COSTS –
SHIPPINGSUBCONTRACTORS[**][**][**]TOTAL OTHER DIRECT COSTS[**][**][**]SUBTOTAL
OTHER DIRECT AND TOTAL LABOR[**][**][**]EXCLUSION FROM BASE FOR
G&A[**][**][**]ADJUSTED BASE FOR G&A[**][**][**]G&A[**][**][**][**]MATERIAL AND
SUBCONTRACTOR HANDLING[**][**][**][**]TOTAL PROPOSED COST EXCLUDING PROFIT
CPFF[**][**][**]PROPOSED FEE CPFF[**][**]GRAND TOTAL PRICE[**][**][**]

8
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

9
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors

Change Order Proposal

2. Labor Detail – The following tables shows the calculations for labor costs
proposed, by labor category:

image_11.jpg [image_11.jpg]
LABOR DETAIL

2020Task DescriptionLabor CategoryHourly RateHoursDirect Labor $ssubCLIN
0002.7[**][**][**][**][**][**][**][**][**][**][**][**][**][**][**][**][**][**][**][**][**][**][**][**]subCLIN
0002.7Grand Total[**][**]

3. Subcontractor Cost Detail
The following tables is a list of the subcontractor costs included in the
proposed prices:
SUBCONTRACTOR COSTS

SubcontractorTask DecsriptionDirect $s[**]subCLIN 0002.7[**][**][**][**]subCLIN
0002.7[**][**][**][**]subCLIN 0002.7[**][**][**][**]subCLIN
0002.7[**][**][**][**]subCLIN 0002.7[**][**][**]subCLIN
0002.7[**][**][**][**]subCLIN 0002.7[**][**][**]Grand Total[**]

10
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Prepared for the Biomedical Advanced Research and Development Authority (BARDA)
Contract - HHSO100201200004I
Emergent Manufacturing Operations Baltimore LLC Change Order Proposal for
Enhancing/Expanding Core Capabilities of the ADM-Bioreactors
Change Order Proposal

6.0Pricing File (MS EXCEL)

Emergent is submitting as an embedded file, to this volume in MS EXCEL format,
the costing buildup worksheet from which the proposed price is generated. Each
table displayed in Section
5.0 of this offer is a separate tab within the file.

[**]
11
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal

--------------------------------------------------------------------------------

Appendix A – Statement of Work for subCLIN 0002.7

Statement of Work (SOW)

The proposed subCLIN 0002.7 includes the purchase, installation and
qualification of [**] additional bioreactors for Areas [**] of Emergent’s CIADM
facility at our Bayview location.
The bioreactors are designed to be [**].
This SOW also includes estimates for labor associated with installation,
engineering and qualification activities as well as contract automation support.
Additional miscellaneous costs include required bioreactor support equipment
12
Emergent Manufacturing Operations Baltimore LLC. – PROPRIETARY Use or disclosure
of the data contained on this sheet is subject to
the restriction on the title page of this Proposal